In this latest rapid-reference memory aid from Diabetes & Primary Care, Pam Brown summarises the doses, indications and licences of the SGLT2 inhibitor class of diabetes drugs in adults.
19 October 2023: Updated to reflect changes in licensing for empagliflozin.
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Kidney Failure Risk Equation does not take into consideration ethnicity and competing risk of death. What are the implications of this?
25 May 2026